Applications of STAGE Imaging in Neurodegenerative Diseases

E. Mark Haacke, PhD Prof. Of Radiology, Wayne State University





STAGE: Standardization of MR Imaging

- STAGE stands for STrategically Acquired Gradient Echo imaging.
- The STAGE imaging protocol is a rapid, multi-contrast sequence and software approach to gain the maximum amount of information with the highest resolution in the least amount of time.
- > STAGE provides 15 pieces of information, 8 qualitative/7 quantitative.
- Depending on the resolution, echo times and repeat times chosen,
 STAGE can be run in 4-6 minutes clinically for 2mm or 6-9 minutes for 1.34mm thick slices with an in-plane resolution of 0.67 x 1mm².















Comparison of 2min, 2mm and 3min, 1.34mm short TR T1W STAGE Protocols: 0.67mm x 1mm in-plane resolution, TE = 5ms

TH=2mm; 2 min per FA TH=1.34mm; 3 min short TE



According to our experience, the resolution of 0.67mm x 1mm x 1.34mm is an optimal cutoff above which the images appear blurry and below which the images take too long to collect and are much noisier.







Applications of STAGE to Parkinson's Disease

- Parkinson's disease (PD) is believed to be the second most common neurodegenerative disease in developed countries with the number of cases expected to increase to 12 million by 2040.
- Differentiating between movement disorders can be difficult and take years to properly diagnose.
- These include: idiopathic PD (IPD), Multiple System Atrophy (MSA), Essential Tremor (ET), Progressive Supranuclear Palsy (PSP), Lewy Body with Dementia (LBD), and REM Sleep Behavior Disorder (RBD).
- STAGE offers a comprehensive PD protocol that provides for quantitative and qualitative MR imaging biomarkers representing changes in neuromelanin in the substantia nigra and locus coeruleus as well as the iron content throughout the deep gray matter (DGM) structures using a template based automatic segmentation of the DGM.
- Visualizing the DGM through their iron content can play a key role in deep brain stimulation (DBS) surgical planning for differentiating between the substantia nigra and subthalamic nucleus.

© 2022 SpinTech MRI, Inc. All rights reserved



Specific indications of STAGE for PD

- PSD: Gives quantitative water content within white matter (WM) lesions.
- **PSD:** May provide a means to monitor neuromelanin (NM) without MTC.
- **True SWI:** Shows the nigrosome-1 (N1) sign which is key for interpreting NM degeneration and distinguishing PD from ET and healthy controls.
- **QSM:** Provides iron content for all the deep gray matter, including the midbrain.
- **QSM:** Makes it possible to delineate the SN from the STN.
- sDIR images: Map whole brain CSF, GM and WM atrophy longitudinally.
- **T1maps:** Quantify T1 and relate this tissue contrast.





3D view of the Subthalamic Nucleus on QSM: Visualizing the deep gray matter and the subthalamic nucleus in particular is vitally important for DBS planning





- > The N1 structure is larger, located posteromedially, can cover up to 5 mm in length and is adjacent to N3 posteriorly.
- > When NM-MRI slice thickness is 1.34mm, N1 structures can be observed in 2-3 slices caudally.
- In PD, the severity and order of loss of NM occur as follows: N1>N2>N4>N3>N5.















STAGE Imaging of Multiple Sclerosis: MS Pathology

• MS is a disease of uncertain etiology with a wide range of symptoms including but not limited to:

Cognitive decline	brain fog	incontinence
loss of muscle coordination	emotional disturbance	loss of ambulation

- MS is diagnosed using MRI via the McDonald criteria involving dissemination in space and time.
- Peri-ventricular, peri-venous lesions are seen throughout the brain and spinal cord, affecting the central nervous system.
- Lesions are typically identified in T2 FLAIR or T1W images, due to their inflammatory nature.
- MS is still thought to be auto-immune in nature, but may in fact be related to:
 - having had Epstein-Barr virus, and
 - a disruption of the endothelium leading to extravasation of lymphocytes.
- Chronic lesions can lead to loss of blood supply and tissue necrosis.

Challenges in Imaging MS

- MS has long been a difficult syndrome to diagnose.
- It has many mimics all showing white matter lesions.
- Some can be separated using the 50% central vein sign rule.
- There may be substantial discordance between conventional MRI findings and clinical syndrome, therefore additional information is needed from imaging examinations
- Recent progress suggests it is possible to differentiate inflammatory from demyelinating inflammatory lesions. The ability to distinguish these states may provide an opportunity for improved therapy.

Specific indications of STAGE for MS

- A) PSD: Gives quantitative water content within white matter (WM) lesions.
- B) PSD: At long TE, this provides clear images of WM comparable to FLAIR.
- C) T1WE: Shows strong GM/WM contrast, dark for lesions with high water content.
- D) SWI/SWI-FLAIR: Shows the central vein sign that is key for interpreting MS.
- E) QSM: Provides iron content in the deep gray matter.
- F) QSM: Increased susceptibility in WM lesions represents demyelination.
- G) sDIR images: Map whole brain CSF, GM and WM atrophy longitudinally.
- H) T1maps: Quantify T1 and are used to help produce CROWN images.







MS MRI Future Directions

- Using STAGE for rapid tissue property mapping
- Mapping water content of lesions
- Measuring venous abnormalities with MICRO
- Measuring flow deficits in the medullary veins
- Measuring flow deficits in the ependymal veins
- Mapping inflammation at the vessel wall pre WMH
- Differentiating demyelinating lesions from purely inflammatory lesions.

